Xenon Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
British Columbia, Canada
Country
British Columbia, Canada
Business Address
200 - 3650 GILMORE WAY, BURNABY, ,
Mailing Address
200 - 3650 GILMORE WAY, BURNABY, ,
Phone
(604) 484-3300
Fiscal Year End
1231
EIN
980661854
Financial Overview
FY2025
$798.14M
Total Assets
$927.92M
Stockholders' Equity
$199.16M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Azetukalner (XEN496) successfully completed Phase 3 clinical trial with positive results, with NDA submission expected by mid-2026.
- Strong financial position with $410.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into late 2027.
Insider Trading
STRONG SELL
3 insiders
20 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.